What is it about?
RSV vaccination was effective in preventing RSV-related illness, including associated health-care use, in adults aged 60 years and older during the 2023-24 respiratory illness season, supporting current recommendations for vaccination in this population.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information on the real-world effectiveness of these vaccines is needed.
Perspectives
This assessment of RSV vaccine effectiveness in a large national cohort shows strong evidence of benefit among individuals aged 60 years and older during the 2023–24 respiratory illness season, including protection against RSV-associated emergency department visits and hospitalizations as well as among subgroups at high risk for severe RSV illness. These findings support current recommendations for RSV vaccination among individuals aged 60 years and older.
Dr. Cynthia Lucero-Obusan
U.S. Department of Veterans Affairs
Read the Original
This page is a summary of: Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study, The Lancet Infectious Diseases, January 2025, Elsevier,
DOI: 10.1016/s1473-3099(24)00796-5.
You can read the full text:
Contributors
The following have contributed to this page
